Navigation Links
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results from the RE-NOVATE(TM) trial demonstrated that oral dabigatran etexilate once daily, administered for an average of 33 days, was non-inferior to enoxaparin, also administered for an average of 33 days, in preventing venous thromboembolism (VTE) and all-cause mortality after total hip replacement surgery. In this trial, the rate of major bleeding associated with dabigatran etexilate was similar to enoxaparin. The incidence of liver enzyme elevations and acute coronary events during the treatment or during the follow-up period did not differ significantly between the treatment groups. These data were presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) today.(i) In clinical trials, dabigatran etexilate is given orally once daily and does not require titration or coagulation monitoring.

Results of the RE-NOVATE trial showed that both oral doses (220mg; 150 mg) of dabigatran etexilate were non-inferior to injected enoxaparin at reducing the risk of thromboembolic disease after primary elective total hip replacement surgery when given for the extended average time period of 33 days. The incidences for the primary efficacy composite endpoint of total VTE and all-cause mortality were 6.0% (dabigatran 220 mg), 8.6% (dabigatran 150 mg), and 6.7% (enoxaparin 40 mg). The incidences of total VTE and all-cause mortality in both dabigatran dose groups were within the pre-specified non- inferiority margin of 7.7%. Safety was evaluated for 3,463 patients receiving study treatment. The incidences of major bleeding events were similar in all treatment groups, 2.0% (dabigatran 220 mg), 1.3% (dabigatran 150 mg), and 1.6% (enoxaparin 40 mg).

Also presented at ISTH was a pooled analysis of major VTE and VTE-related mortality after primary elective knee and hip replacement surgery across more than 8,000 randomiz
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/27/2014)... -- Varian Medical Systems (NYSE: VAR) today broke ground on new ... City manufacturing facility and allow for the consolidation ... to ultimately create 1,000 new full time jobs in ... " Utah is home to hardworking people ... be credited with Varian,s success in the manufacturing of our ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014   Los ... now offers AcceleDent® Aura to patients who want to ... orthodontic care available at the OrthoSpaceship, all patients have ... better-looking teeth. This system can be used by most ... their rate of progress by using the AcceleDent® Aura ...
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:8/27/2014)... Aeroflow Healthcare has announced it ... of a strategic expansion of its durable medical ... ownership of new businesses through additional resources and ... , Last week, the company announced that it ... increase service in the High Point/Greensboro/Winston-Salem area. This ...
(Date:8/27/2014)... A St. Louis law firm that represents ... that the C.R. Bard multidistrict litigation (MDL), an MDL ... lawsuits, recently filed a new pretrial order (PTO) on ... discovery process, and more specifically to the management of ... & Lowe is a law firm practicing defective medical ...
(Date:8/27/2014)... New York (PRWEB) August 28, 2014 ... Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
(Date:8/27/2014)... August 28, 2014 Recently, BambooIndustry.com, an innovative ... has announced that new bamboo panels are now ... providing deep discounts for clients worldwide. All people that place ... discounted rate, from 10 to 30 percent off. , ... new panels. “At the moment, all our new and old ...
(Date:8/27/2014)... August 28, 2014 DiaSorin has announced ... of 1,25 Dihydroxyvitamin D,” will feature guest speaker Dr. ... George Institute for Health and Healing Integrative Medicine. Dr. ... Penny George Institute for Health and Healing and as ... Care, Minneapolis, Minnesota. He also serves as a co-editor ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... 2008 at 11:00 AM ET, LIVINGSTON, N.J., May ... recognized leader in advanced,injection technologies, today announced that the ... ended March 31, 2008 on Thursday,May 15, 2008., ... 2008, beginning,at 11:00 AM Eastern time, and invites all ...
... funding to PBTF Institute at Duke accelerates search for ... ... The Pediatric Brain,Tumor Foundation (PBTF) is giving an additional $6 million ... to $12 million., To view the Multimedia News Release, go ...
... for prehypertensive people in morning use, researchers report , , ... can control prehypertension, but only if it is taken ... taken every morning didn,t lower the blood pressure of ... C. Hermida reported Wednesday at the American Society of ...
... Del., May 14 AstraZeneca (NYSE:,AZN) today announced ... has,approved SEROQUEL(R) (quetiapine fumarate tablets) for the maintenance,treatment ... therapy to,lithium or divalproex. SEROQUEL is approved by ... also the only single agent approved by the ...
... AMRN ) today announced a private placement ... ("ADSs") with several new,institutional and accredited investors, and ... $60 million funded over two equal tranches., ... agreements for,gross proceeds of up to $56 million, ...
... Mass., and SYDNEY, Australia, May 14 /PRNewswire-FirstCall/,-- HeartWare Limited ... an investor presentation at the Seventh Annual JMP Securities ... Wednesday, May 21, 2008. The,conference is being held at ... webcast of the Company,s presentation at the conference will ...
Cached Medicine News:Health News:Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008 2Health News:Video: Pediatric Brain Tumor Foundation Gives $6 Million Grant to Duke 2Health News:Aspirin at Bedtime Lowers Blood Pressure 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2
... a user friendly computerized medical record system ... and productivity of the practice as well ... documentation. It provides clinical templates for commonly ... It also contains an exhaustive database to ...
... GE Medical Systems Information ... see for yourself how ... Physician Office - Practice ... Manager) can simplify your ...
... 2V slit lamp is ... lamp that is designed ... tower and has standard ... Revolutionary design provides increased ...
... ReSeeVit CR-DGi Retinal Camera System is an ... retinal segment images for documentation, diagnosis and ... CR-DGi retinal camera for optimal performance. We ... designed for anterior segment images. ReSeeVit is ...
Medicine Products: